Original news and analysis on international IP policy
El Medicines Patent Pool y la compañía farmacéutica Gilead Sciences ha anunciado hoy un acuerdo de licencia para permitir la producción medicamentos clave para el combate contra el VIH a un menor costo y en una formulación más fácil de usar, haciéndolos más accesibles a los países en desarrollo.. El acuerdo se extiende al uso de tratamientos para la hepatitis B por primera vez.
Civil society groups say a leaked document from regional free trade negotiations between countries bordering the Pacific Ocean shows the United States favouring giant pharmaceutical companies at the expense of public health. Separately, the tobacco industry is allegedly also trying to push for a clause to prevent plain packaging.
The Medicines Patent Pool and pharmaceutical company Gilead Sciences today announced a breakthrough licence agreement to allow for the production of key HIV medicines at lower cost and in an easier-to-use formulation, making them more accessible to developing countries. The agreement also opens up the use of treatments for Hepatitis B for the first time.
Concern over non-communicable diseases - traditionally a more developed-country set of problems like diabetes - is energising the international public health policy community. But representatives of the public interest are still grappling with their response.
The joint United Nations Programme on HIV/AIDS (UNAIDS) today praised the commitment made by India's Commerce Minister not to negotiate stronger intellectual property rights provisions that could undermine India's global leadership in the production of affordable generic AIDS drugs.
A diverse team of global experts on public health research and development will meet this week behind closed doors to analyse proposals for ways to fund R&D on diseases afflicting poor populations – and for who should coordinate such global efforts.
A Canadian bill to improve global access to medicines might get another shot in the new Parliament, writes Daniele Dionisio.
For the past ten years, the United States Supreme Court has steadily chipped away at patent rights. But this term, the court abruptly reversed direction. In two weeks, the high court issued rulings in three patent cases, and in every one upheld the legal rights of inventors. It is unclear, however, how big a win this really was for patent rights.
The US House of Representatives this evening passed HR 1249 – the closest action patent reform has come to being enacted into law in the past 10 years. But there were some changes made to the bill.
The head of Geneva-based UNITAID, an innovative drug purchasing system for the global poor, will leave the post this month.